Please login to the form below

Not currently logged in
Email:
Password:

FDA clears two GSK melanoma drugs

Tafinlar and Mekinist approved in the US along with companion diagnostic

FDA clears two GSK melanoma drugs

The US FDA has approved two personalised medicines for advanced melanoma developed by GlaxoSmithKline (GSK), along with a new companion diagnostic developed by bioMerieux to guide their use.

The regulator gave a green light to GSK's BRAF inhibitor Tafinlar (dabrafenib) and MEK inhibitor Mekinist (trametinib) as monotherapies to treat advanced or unresectable melanoma patients who have mutations in the BRAF gene.

Tafinlar is approved to treat patients with melanoma whose tumours express the BRAF V600E gene mutation, while Mekinist will be used in patients whose tumours express the BRAF V600E or V600K mutations, said the FDA. Patients suitable for treatment with the new drugs will be selected using bioMerieux's THxID BRAF test.

The two drugs are the third and fourth new drugs for melanoma to be approved in the last couple of years, after Daiichi Sankyo/ Roche's Zelboraf (vemurafenib) - which also targets BRAF-positive tumours - and Bristol-Myers Squibb's anti-CTLA4 immunotherapy Yervoy (ipilimumab). Both drugs were given the nod in 2011.

Mutations in the BRAF gene are involved in around 50 per cent of malignant melanomas, according to the Institute of Cancer Research (ICR), so it is expected that Yervoy will lead the market in future as it can be used to treat any melanoma patient, regardless of their genetic profile.

Yervoy has already got off to a fantastic start in the marketplace, bringing in $706m in sales last year, and is expected to reach up to $2bn at peak, with Zelboraf following behind with Roche reporting CHF 234m ($244m) in sales last year. Zelboraf has been tipped to reach $1bn at peak, with GSK's two products managing a little less ($350m-$500m) apiece.

GSK is also carrying out a trial of Tafinlar and Mekinist in combination, and some analysts believe the double-whammy of BRAF and MEK inhibition - which seems to alleviate some of the side effects of BRAF inhibition whilst reducing the risk of tumour resistance - could be help GSK's drugs leapfrog Zelboraf and claim the number two spot in melanoma therapy in the coming years.

Roche is not sitting still, however, and said recently it has started a phase III study of Zelboraf alongside Exelixis' MEK inhibitor GDC-0973.

GSK said it will be making Tafinlar and Mekinist available for prescription in the US "no later than in the early third quarter of 2013".

30th May 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics